COVID-19 has a high infection rate and mortality, and serious complications such as heart
injury cannot be ignored. Cardiac dysfunction occurred in COVID-19 patients, but the law and
mechanism of cardiac dysfunction remains unclear. The occurrence of progressive inflammatory
factor storm and coagulation dysfunction in severe and fatal cases of NCP points out a new
direction for reducing the incidence of severe and critically ill patients, shortening the
length of duration in severe and critically ill patients and reducing the incidence of
complications of cardiovascular diseases. Aspirin has the triple effects of inhibiting virus
replication, anticoagulant and anti-inflammatory, but it has not received attention in the
treatment and prevention of NCP. Although Aspirin is not commonly used in the guidelines for
the treatment of NCP, it was widely used in the treatment and prevention of a variety of
human diseases after its first synthesis in 1898. Subsequently, aspirin has been confirmed to
have antiviral effect on multiple levels. Moreover, one study has confirmed that aspirin can
inhibit virus replication by inhibiting prostaglandin E2 (PGE2) in macrophages and
upregulation of type I interferon production. Subsequently, pharmacological studies have
found that aspirin as an anti-inflammatory and analgesic drug by inhibiting cox-oxidase
(COX). Under certain conditions, the platelet is the main contributor of innate immune
response, studies have found that in the lung injury model in dynamic neutrophil and platelet
aggregation.
In summary, the early use of aspirin in covid-19 patients, which has the effects of
inhibiting virus replication, anti-platelet aggregation, anti-inflammatory and anti-lung
injury, is expected to reduce the incidence of severe and critical patients, shorten the
length of hospital duration and reduce the incidence of cardiovascular complications.